Hormone guide
Hormones & Peptides

Calcitonin

Calcitonin is a 32-amino-acid peptide hormone produced by thyroid parafollicular C-cells that lowers blood calcium by inhibiting osteoclast-mediated bone resorption and increasing renal calcium excretion. Pharmaceutical forms — salmon, eel (elcatonin), and synthetic human — are used for acute hypercalcemia, Paget disease of bone, short-term vertebral fracture pain, and historically for osteoporosis. Regulatory agencies have restricted long-term use due to a small increased cancer signal with prolonged salmon calcitonin exposure.

Calcitonin-salmon
Eel calcitonin
Elcatonin
Fortical
Human calcitonin
Miacalcin
Salmon calcitonin

This guide covers all common forms and variations of calcitonin in one place. Use the sections below to find the form that fits your situation.

How it works in the body

Calcitonin is a 32-amino-acid peptide hormone that binds to calcitonin receptors (CTRs) expressed on osteoclasts and renal tubular cells. In osteoclasts, receptor activation raises intracellular cAMP, which rapidly reduces resorptive activity — the cells retract their ruffled border, decreasing bone breakdown and the release of calcium and phosphate into circulation.

In the kidney, calcitonin reduces tubular reabsorption of calcium and phosphate, increasing their urinary excretion and thereby lowering serum calcium through a second independent mechanism.

Calcitonin receptors are also expressed in the central nervous system. The analgesic effect observed after acute vertebral fractures is attributed to central modulation of nociceptive pathways; calcitonin gene-related peptide (CGRP), which is co-encoded on the same gene, may also contribute to pain signaling, but the precise analgesic mechanism remains incompletely characterized.

Calcitonin molecular structure
2D molecular structure from PubChem, National Library of Medicine.

Body systems

Skeletal system
Renal system
Endocrine system
Nervous system (analgesia)

Associated molecules

Calcitonin
Parathyroid hormone (PTH)
cAMP
Calcitonin gene-related peptide (CGRP)

Track it lightly

If you are prescribed calcitonin, track short-term pain changes, serum calcium levels, and any adverse effects, and discuss treatment duration and alternatives with your clinician.

Trying this? Start tracking it here.

Background

Calcitonin was identified in the early 1960s as a circulating factor from thyroid parafollicular (C) cells that opposes parathyroid hormone's hypercalcemic action. Salmon calcitonin was developed for pharmaceutical use because it is substantially more potent and longer-acting in humans than the endogenous human sequence. From the 1970s onward, injectable and later intranasal salmon calcitonin became available for Paget disease, acute hypercalcemia, and vertebral fracture pain. By the 1990s it was also used for osteoporosis, but fracture-prevention evidence never matched that of bisphosphonates. In 2013, the European Medicines Agency restricted long-term salmon calcitonin use after meta-analyses suggested a small increased cancer risk with chronic exposure, shifting its role firmly toward short-term indications.

Evidence snapshot

Clinical evidence supports calcitonin's short-term effectiveness for lowering serum calcium in acute hypercalcemia and for reducing biochemical markers of bone turnover. The analgesic benefit for acute vertebral fracture pain is supported by multiple randomized controlled trials, though effect sizes are modest and benefits are primarily limited to the first few weeks of treatment.

For chronic fracture risk reduction in osteoporosis, evidence is weak and inconsistent. Systematic reviews and regulatory assessments have found limited fracture-prevention benefit relative to bisphosphonates or denosumab. Regulatory agencies identified a small but uncertain increased risk of malignancy with long-term salmon calcitonin use, prompting label restrictions and withdrawal of the chronic osteoporosis indication in several jurisdictions.

Calcitonin remains useful in selected short-term situations: emergency management of hypercalcemia, symptomatic Paget disease, analgesia in the acute phase after vertebral fracture, and as a serum tumor marker for medullary thyroid carcinoma. It is not a first-line or long-term option for osteoporosis prevention.

Bioavailability and formulations

Calcitonin is a peptide and is not bioavailable when taken orally in conventional form. Available pharmaceutical formulations include intranasal sprays (salmon calcitonin 200 IU per actuation) and parenteral injections (100 IU intramuscular or subcutaneous). Intranasal bioavailability is substantially lower than parenteral routes, which is why intranasal doses are expressed at higher IU values. Oral peptide delivery technologies and sustained-release formulations have been investigated but are not established in routine clinical practice.

Populations studied and efficacy

Clinical trials have primarily enrolled postmenopausal women with osteoporosis, patients with Paget disease, and individuals with acute vertebral compression fractures. Evidence consistently supports short-term reductions in bone resorption markers and modest analgesia after vertebral fracture. Large, consistent fracture-prevention benefits — comparable to those demonstrated for bisphosphonates or denosumab — have not been demonstrated for calcitonin, and regulatory agencies concluded the benefit-risk balance does not support chronic osteoporosis use.

Long-term safety and regulatory guidance

Meta-analyses and regulatory reviews, most notably the 2013 EMA assessment, identified a small but statistically uncertain increased incidence of malignancies (predominantly prostate and digestive cancers) in patients using salmon calcitonin long-term. The EMA recommended restricting calcitonin to short-term use and withdrawing or restricting the chronic osteoporosis indication. Clinicians should weigh short-term symptomatic benefits against this unresolved safety signal and prefer established first-line agents for fracture prevention.

Diagnostic uses

Serum calcitonin is an established biomarker for medullary thyroid carcinoma (MTC) detection and post-treatment surveillance. Baseline measurement and, where available, stimulated calcitonin testing (using intravenous calcium infusion) are used in endocrinology practice. Elevated calcitonin from non-thyroidal causes — chronic kidney disease, other neuroendocrine tumors, proton pump inhibitor use, and hypercalcemia itself — should be considered in interpretation. Thresholds and protocols are assay-dependent and should follow current endocrine society guidelines.

Compound variations

Salmon calcitonin

Calcitonin

The most commonly used pharmaceutical form; substantially more potent and longer-acting in humans than human calcitonin. Available as intranasal spray (Miacalcin, Fortical) and injectable formulations.

Common use case

Short-term treatment of acute hypercalcemia, vertebral fracture pain, and active Paget disease.

Dosage note

Intranasal: 200 IU once daily, alternating nostrils. Injectable: 100 IU SC or IM every 24–48 hours for acute indications. Duration should be limited per regulatory guidance.

Synthetic human calcitonin

Calcitonin

Matches the endogenous 32-amino-acid sequence but is less potent than salmon calcitonin; less commonly used in clinical practice.

Common use case

Research applications and situations where a human-sequence product is clinically preferred; rarely used in routine practice.

Dosage note

Formulation-dependent; human calcitonin products have limited commercial availability in most markets.

Elcatonin (eel calcitonin)

Calcitonin

An eel-derived calcitonin analog with structural modifications that confer resistance to enzymatic degradation; used in Japan and some other countries for bone pain and osteoporosis.

Common use case

Short-term pain relief for vertebral fractures and bone disorders in regions where the product is approved and available.

Dosage note

Dosing varies by country and product labeling; follow local prescribing information.

Synthetic calcitonin analogues and novel delivery systems

Calcitonin

Investigational analogues and alternative delivery technologies — including oral peptide formulations and sustained-release injectables — are being studied for improved pharmacokinetics or safety profiles.

Common use case

Research and clinical trials; not available in routine clinical practice.

Dosage note

Dosing and safety are protocol-specific; not applicable outside investigational settings.

Dosage and best practices

Dosage principles

  • Intranasal salmon calcitonin: 200 IU once daily (one spray; alternating nostrils daily). Clinical use is typically limited to weeks for pain management after vertebral fracture.
  • Injectable salmon calcitonin: 100 IU subcutaneously or intramuscularly every 24–48 hours for hypercalcemia or Paget disease; frequency is adjusted based on clinical response and tolerability.
  • Analgesic use after vertebral fracture: trials used intranasal 200 IU/day or 100 IU parenteral for 2–6 weeks and demonstrated short-term pain reduction. Prolonged courses are not recommended given uncertain long-term benefit and safety signals.
  • Diagnostic use (medullary thyroid carcinoma): serum calcitonin measurement and stimulated testing (calcium or pentagastrin stimulation where available) follow laboratory- and assay-specific reference ranges. Interpretation and protocol should follow endocrinology guidance.

Best practices

  • Reserve calcitonin for short-term indications (acute hypercalcemia, acute vertebral fracture pain, active Paget disease) and under specialist guidance; reassess need at regular intervals.
  • Monitor serum calcium and renal function during treatment. Biochemical markers of bone turnover typically fall within days to weeks of initiating therapy.
  • For intranasal formulations: use alternate-nostril technique, prime the pump before first use, and avoid inhaling through the nose during administration. Injectable forms are given SC or IM per product instructions.
  • In patients with fish or salmon allergy, avoid salmon-derived calcitonin; discuss alternatives with the prescribing clinician.
  • For osteoporosis, evaluate whether a bisphosphonate, denosumab, or other approved antiresorptive is more appropriate before selecting calcitonin.

Literature and references

Common questions

Is calcitonin effective for long-term osteoporosis prevention?

No. Long-term fracture-prevention data are weak and inconsistent, and calcitonin does not match the efficacy of bisphosphonates or denosumab. Combined with regulatory concerns about prolonged use, it is not recommended as first-line or long-term osteoporosis therapy.

Can I use salmon calcitonin if I am allergic to fish?

Caution is warranted. Salmon-derived calcitonin carries a risk of allergic cross-reactivity in people with fish or salmon allergy. Discuss your allergy history with your clinician; alternatives include synthetic human calcitonin or non-calcitonin osteoporosis therapies.

How quickly does calcitonin lower high blood calcium?

Serum calcium can begin falling within hours of parenteral calcitonin administration, making it useful as a temporizing measure in acute hypercalcemia. The effect is modest and transient; concurrent investigation and treatment of the underlying cause are essential.

What monitoring is needed during calcitonin treatment?

Monitor serum calcium and renal function during the course of treatment, and watch for common adverse effects (nausea, flushing, nasal irritation). For any course extending beyond a few weeks, reassess the benefit-risk balance given regulatory cautions about prolonged use.

Can calcitonin be used alongside other osteoporosis drugs?

Sequential or short-term adjunctive use is described in the literature, but combining calcitonin with other potent antiresorptives (bisphosphonates, denosumab) increases the risk of hypocalcemia. Any combination should be individualized and monitored with your clinician.

Related guides